Related Experiment Video
Updated: Oct 25, 2025
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives
Amber Gibson1, Carlos Hernandez1, Fiorela N Hernandez Tejada1
1Department of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Insights
Asparaginase therapy is crucial for acute lymphoblastic leukemia (ALL) treatment but can cause pancreatitis. New protocols may alter pancreatitis risk, and pharmacogenomics could identify high-risk patients.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Asparaginase is a vital treatment for acute lymphoblastic leukemia (ALL), particularly in high-risk patients.
- Asparaginase-associated pancreatitis (AAP) is a significant toxicity that can lead to treatment discontinuation and increased relapse risk.
- Recent ALL treatment protocols involve higher asparaginase doses and longer-acting formulations, raising questions about AAP incidence.
Purpose of the Study:
- To review the incidence of asparaginase-associated pancreatitis (AAP) in recent acute lymphoblastic leukemia (ALL) trials.
- To explore the role of pharmacogenomics in identifying patients at high risk for severe AAP.
- To discuss the implications of increased asparaginase dosing and novel formulations on AAP rates and patient re-exposure strategies.
Main Methods:
- Literature review of recent clinical trials investigating asparaginase therapy in ALL.
- Analysis of existing pharmacogenomic data, including single nucleotide polymorphisms (SNPs), related to AAP.
- Discussion of treatment strategies for managing AAP and patient re-challenge after initial toxicity.
Main Results:
- The incidence of AAP in recent trials is under evaluation, especially with evolving treatment protocols.
- Pharmacogenomic data, such as specific SNPs, shows potential for predicting severe AAP risk.
- Cautious re-exposure to asparaginase after an initial AAP episode requires careful consideration.
Conclusions:
- Understanding AAP incidence and risk factors is critical for optimizing ALL treatment.
- Pharmacogenomics offers a promising avenue for personalized risk assessment and management of AAP.
- Further research is needed to guide safe and effective asparaginase re-administration post-pancreatitis.
Abstract:
Asparaginase therapy is a vital agent in the treatment of acute lymphoblastic leukemia (ALL), with increasing evidence of its high importance in high-risk ALL populations. However, despite the clear clinical and biological benefits of asparaginase therapy, many patients experience toxicities. A well-known treatment-limiting toxicity is asparaginase-associated pancreatitis (AAP). If severe, it necessitates discontinuation of asparaginase therapy, which can lead to a higher risk of relapse in patients with ALL. New protocols for ALL therapy have increased overall total doses of asparaginase therapy in select high-risk populations and have incorporated longer half-life formulations of pegylated asparaginase. Treatment drug monitoring has also allowed assurance of adequate levels of asparagine depletion throughout treatment. It is currently unknown if these changes will increase rates of AAP. Interestingly, important pharmacogenomics data, such as single nucleotide polymorphisms, can identify patients at the highest risk for severe AAP. The incidence of AAP in recent trials, current pharmacogenomic data that could further our understanding of the disease, and the importance of cautiously re-exposing patients to further asparaginase treatment after an initial episode of AAP are discussed.
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption